Recommendations for diagnostics and therapy of gastrointestinal stromal tumors (GIST) in 2008;Zasady postepowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2008 roku

Nowotwory

Volumn 58, Issue 6, 2008, Pages 537-548

  Ruka, Włodzimierz ^a   Rutkowski, Piotr ^a,c   Kulig, Jan ^b   Osuch, Czesław ^b   Krzakowski, Maciej ^c   Siedlecki, Janusz A ^c   Nasierowska Guttmejer, Anna ^d   Sygut, Jacek ^e   Limon, Janusz ^f   Jeziorski, Arkadiusz ^g   Grzesiakowska, Urszula ^c   Ptaszyński, Konrad ^c   Słuszniak, Janusz ^e   Polkowski, Wojciech ^h   Stelmach, Andrzej ⁱ   Starosławska, Elzbieta ^j   Polkowski, Marcin ^c   Bebenek, Marek ^k   Matłok, Maciej ^b   Solska, Ewa ^l  

^a Klinika Nowotworów Tkanek Miekkich i Ko ci Centrum Onkologii   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Szpital MSWiA w Warszawie ^*  (Poland)

^e wi tokrzyskie Centrum Onkologii W Kielcach   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h MEDICAL UNIVERSITY OF LUBLIN   (Poland)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j Centrum Onkologii Ziemi Lubelskiej   (Poland)

^k Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^l Wojewódzkie Centrum Onkologii W Gda sku   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

CANCER GROWTH; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PATHOGENESIS; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; TUMOR VOLUME;

EID: 60449091542     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
2. Fletcher CDM, Berman JJ, Corless C i wsp. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology 2002; 33: 459-65.
3. Kindblom LG, Remotti HE, Aldenborg F i wsp. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the interstitial cell of Cajal. Am J Pathol 1998; 152: 1259-69.
4. Casali PG, Jost L, Reichardt P, Schlemmer M i wsp. Gastrointestinal stroma tumors: eSMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii35-ii38.
5. Demetri GD, von Mehren M, Blanke CD i wsp. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
6. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI 571). Ann Surg Oncol 2002; 9: 831-9.
7. Nilsson B, Bumming P, Meis-Kindblom JM i wsp. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era. Cancer 2005; 103: 821-9.
8. Ruka W, Rutkowski P, Nowecki ZI i wsp. Przeżycia chorych na rozsiany i nieoperacyjny GIST leczonych imatinibem - analiza etapowa Klinicznego Rejestru GIST. The outcomes of patients with metastatic/ inoperable gastrointestinal stromal tumors (GIST) treated with imatinib - an interim multicenter analysis of Polish Clinical GIST Registry. Nowotwory J Oncol 2005; 55: 195-9.
9. Urbańczyk K, Limon J, Korobowicz E i wsp. Gastrointestinal stromal tumors: a multicenter experience. Pol J Pathol 2005; 56: 51-61.
10. Nowecki ZI, Rutkowski P, Lindner B i wsp. Nowotwory podścieliskowe przewodu pokarmowego (GIST- gastrointestinal stromal tumor) umiejscowione w jelicie cienkim i rozpoznawane przedoperacyjnie jako nowotwory narzadu rodnego. Gin Pol 2005; 76: 855-62.
11. Debiec-Rychter M, Dumez H, Judson I i wsp. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689-95.
12. Heinrich MC, Corless CL, Demetri GD i wsp. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
13. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25.
14. Debiec-Rychter M, Sciot R, Le Cesne A i wsp. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
15. DeMatteo RP, Lewis JJ, Leung D i wsp. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231; 51-58.
16. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol 2006; 18: 386-95.
17. Rutkowski P, Nowecki ZI, Michej W i wsp. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumors (GISTs). Ann Surg Oncol 2007; 14: 2018-27.
18. Eisenberg BL, I. Judson. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465-75.
19. DeMatteo R, Owzar K, Maki R iwsp. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007; 25 (18S; June 20 Suppl): 10079.
20. Verweij J, Casali PG, Zalcberg J i wsp. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.
21. Blanke CD, Demetri GD, von Mehren M i wsp. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5.
22. Blanke CD, Rankin C, Demetri GD i wsp. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-32.
23. Rutkowski P, Nowecki ZI, Debiec-Rychter M i wsp. Predictive factors for long term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Ca Res Clin Oncol 2007; 133: 589-97.
24. Therasse P, Arbuck SG, Eisenhauer EA i wsp. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
25. Choi H, Charnsangavej C, de Castro Faria S i wsp. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-28.
26. Zalcberg JR, Verweij J, Casali PG i wsp. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-7.
27. Van Glabbeke M, Verweij J, Casali PG i wsp. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-804.
28. Heinrich MC, Corless CL, Blanke DC i wsp. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 29: 4764-74.
29. Demetri GD, van Oosterom AT, Garrett CR i wsp. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368: 1329-38.
30. Reichardt P, Kang YK, Ruka W i wsp. Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. J Clin Oncol 2007; 25(18S): Abs 10022.
31. George S, Blay JY, Casali PG i wsp. Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. J Clin Oncol 2007; 25 (18 suppl): Abs 10015.
32. Rutkowski P, Nowecki ZI, Nyckowski P i wsp. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 4: 304-11.
33. Raut CP, Posner M, Desai J i wsp. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-31.